Skip to main content

Advertisement

SpringerLink
Log in

Herbal therapy in migraine

  • SESSION IV UNCONVENTIONAL TREATMENTS
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

The use of herbal therapies is ancient and increasing worldwide. There is a growing body of evidence supporting the efficacy of various “complementary” and alternative medicine approaches in the management of headache disorders. Promising tools to treat migraine patients are herbal products. In particular constituents of Petasites hybridus, Tanacetum Parthenium and Ginkgo Biloba have shown antimigraine action in clinical studies. A miscellaneous of recreational drugs and other herbal remedies have been supposed to have a role in headache treatment but quality of clinical studies in this field is low and inconclusive. Further research is warranted in this area.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Diener HC (2013) Headache: insight, understanding, treatment and patient management. Int J Clin Pract Suppl 178:33–36

    Article  PubMed  Google Scholar 

  2. D’Andrea G, Bussone G, Allais G, Aguggia M, D’Onofrio F, Maggio M, Moschiano F, Saracco MG, Terzi MG, Petretta V, Benedetto C (2009) Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. Neurol Sci 30(Suppl 1):121–124

    Article  Google Scholar 

  3. Giles M, Ulbricht C, Khalsa KP, Kirkwood CD, Park C, Basch E (2005) Butterbur: an evidence-based systematic review by the natural standard research collaboration. J Herb Pharmacother 5(3):119–143

    Article  PubMed  Google Scholar 

  4. Pareek A, Suthar M, Rathore GS, Bansal V (2011) Feverfew (Tanacetum parthenium L): asystematic review. Pharmacogn Rev 5(9):103–110

    Article  PubMed Central  PubMed  Google Scholar 

  5. Tassorelli C, Greco R, Morazzoni P, Riva A, Sandrini G, Nappi G (2005) Parthenolide is the component of tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: studies in a animal model of migraine. Cephalalgia 25:612–621

    Article  CAS  PubMed  Google Scholar 

  6. Aviram A, Tsoukias M, Melnick SJ, Resek AP, Ramachandran C (2012) Inhibition of nitric oxide synthesis in mouse macrophage cells by feverfew supercritical extract. Phytother Res 26:541–545

    Article  PubMed  Google Scholar 

  7. Materazzi S, Benemei S, Fusi C, Gualdani R, De Siena G, Vastani N, Andersson DA, Trevisan G, Moncelli MR, Wei X, Dussor G, Pollastro F, Patacchini R, Appendino G, Geppetti P, Nassini R (2013) Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel. Pain 154:2750–2758

    Article  CAS  PubMed  Google Scholar 

  8. Vogler BK, Pittler MH, Ernst E (1998) Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 18:704–708

    Article  CAS  PubMed  Google Scholar 

  9. Ernst E, Pittler MH (2000) The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutr 3(4A):509–514

    Article  CAS  PubMed  Google Scholar 

  10. Johnson ES, Kadman NP, Hylands DM, Hylands PJ (1985) Efficacy of feverfew as prophylactic treatment of migraine. Br Med J 291:569–573

    Article  CAS  Google Scholar 

  11. Pittler MH, Ernst E (2004) Feverfew for preventing migraine (Review). Cochrane Database Syst Rev, Issue 1 CD002286

  12. Maizeles M, Blumenfeld A, Burchette R (2004) A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 44:885–890

    Article  Google Scholar 

  13. Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH (2002) The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis- a double-blind, multicentre, randomized placebo controlled dose-response study. Cephalalgia 22:523–532

    Article  CAS  PubMed  Google Scholar 

  14. Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH (2005) Efficacy and safety of 6.25 mg t.i.d. feverfew C02 –extract (Mig-99) in migraine prevention- a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 25:1031–1041

    Article  CAS  PubMed  Google Scholar 

  15. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E (2012) Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology 78(17):1346–1353 (stessa voce bibliografica n.12 del paragrafo Petasites)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Cady RK, Goldstein J, Nett R, Mitchell R, Beach ME, Browning R (2011) A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraine. Headache 51:1078–1086

    Article  PubMed  Google Scholar 

  17. Eaton J (1998) Butterbur, herbal help for migraine. Nat Pharm 2:23–24

    Google Scholar 

  18. Taylor FR (2011) Nutraceuticals and headache: the biological basis. Headache 51(3):484–501

    Article  PubMed  Google Scholar 

  19. Sun-Edelstein C, Mauskop A (2011) Alternative headache treatments: nutraceuticals, behavioral and physical treatments. Headache 51(3):469–483

    Article  PubMed  Google Scholar 

  20. Grossmann M, Svhmidramsi H (2000) An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 38(9):430–435

    Article  CAS  PubMed  Google Scholar 

  21. Diener HC, Rahlfs VW, Danesch U (2004) The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 51:89–97

    Article  CAS  PubMed  Google Scholar 

  22. Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A (2004) Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 63(12):2240–2244

    Article  CAS  PubMed  Google Scholar 

  23. Kälin P (2003) The common butterbur (Petasites hybridus)–portrait of a medicinal her. Forsch Komplement Klass Naturheilkd 10(Suppl 1):41–44

    Google Scholar 

  24. Pothmann R, Danesch U (2005) Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache 45:196–203

    Article  PubMed  Google Scholar 

  25. Oelkers-Ax R, Leins A, Parzer P et al (2008) Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study. Eur J Pain 12:301–313

    Article  PubMed  Google Scholar 

  26. Utterback G, Zacharias R, Timraz S, Mershman D (2014) Butterbur extract: prophylactic treatment for childhood migraines. Complement Therapie Clin Pract 20:61–64

    Article  Google Scholar 

  27. McKenna KM, Darlington CL, Smith PL (2001) Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med 7:70–90

    CAS  PubMed  Google Scholar 

  28. Williams B, Watanabe CMH, Schultz PG, Rimbach G, Kruker T (2004) Age-related effects of Ginkgo Biloba extracts on synaptic plasticity and excitability. Neurobiol Aging 25:955–962

    Article  PubMed  Google Scholar 

  29. Akisu M, Kultursay N, Coker I, Huseyinov A (1998) Platelet-activating factor is an important mediator in hypoxic ischemic brain injury in the newborn rat. Flunarizine and Ginkgo Biloba extracts reduce PAF concentration in the brain. Biol Neonate 74(6):439–444

    Article  CAS  PubMed  Google Scholar 

  30. D’Andrea G, Hasselmark L, Alecci M, Cananzi A, Perini F, Welch KMA (1994) Platelet secretion from dense and α-granules in vitro in migraine with or without aura. J Neurol Neurosurg Psychiatry 57(5):557–561

    Article  PubMed Central  PubMed  Google Scholar 

  31. Sarchielli P, Alberti A, Coppola F, Baldi A, Gallai B, Floridi A, Capecchi G, Gallai V (2004) Platelet-activating factor (PAF) in internal jugular venous blood of migraine without aura patients assessed during migraine attacks. Cephalalgia 24:623–630

    Article  CAS  PubMed  Google Scholar 

  32. Allais G, D’Andrea G, Maggio M, Benedetto C (2013) The efficacy of Ginkgolide B in the acute treatment of migraine aura: an open preliminary trial. Neurol Sci 34(S1):S161–S163

    Article  PubMed  Google Scholar 

  33. Usai S, Grazzi L, Andrasik F, Bussone G (2010) An innovative approach for migraine prevention in young age: a preliminary study. Neurol Sci 31(S1):S181–S183

    Article  PubMed  Google Scholar 

  34. Esposito M, Carotenuto M (2011) Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study. Neurol Sci 32:79–81

    Article  PubMed  Google Scholar 

  35. Esposito M, Ruberto M, Pascotto A, Carotenuto M (2012) Nutraceutical preparations in childhood migraine prophylaxis: effects on headache outcomes including disability and behavior. Neurol Sci 33:1365–1368

    Article  PubMed  Google Scholar 

  36. Orr SL, Venkateswaran S (2014) Nutraceuticals in the prophylaxis of pediatric migraine: Evidence-based review and recommendations. Cephalalgia: 1–16

  37. Evans RW, Ramadan NM (2004) Expert opinion: are cannabis-based chemicals helpful in headache? Headache 44:726–727

    Article  PubMed  Google Scholar 

  38. Robbins MS, Tarshish S, Solomon S, Grosberg BM (2009) Cluster attacks responsive to recreational cannabis and dronabinol. Headache 49:914–916

    Article  PubMed  Google Scholar 

  39. Volfe Z, Dvilansky A, Nathan I (1985) Cannabinoid block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res 5:243–246

    CAS  PubMed  Google Scholar 

  40. Fan P (1995) Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 73:907–910

    CAS  PubMed  Google Scholar 

  41. Akerman S, Kaube H, Goadsby PJ (2004) Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol 142(8):1354–1360

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Akerman S, Kaube H, Goadsby PJ (2004) Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther 309(1):56–63

    Article  CAS  PubMed  Google Scholar 

  43. Akerman S, Holland PR, Lasalandra MP, Goadsby PJ (2013) Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and “triptan” receptors: implications in migraine. J Neurosci 33(37):14869–14877

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Kazemi H, Rahgozar M, Speckmann EJ, Gorji A (2012) Effect of cannabinoid receptor activation on spreading depression. Iran J Basic Med Sci 15(4):926–936

    CAS  PubMed Central  PubMed  Google Scholar 

  45. Anand KS, Dhikav V (2012) Migraine relieved by chilis. Headache 52(6):1041

    Article  PubMed  Google Scholar 

  46. Benemei S, Geppetti P (2013) Migraine relief by chilis and other alternative medications: evidence indicates a central role for TRP channels. Headache 53(7):1162–1163

    Article  PubMed  Google Scholar 

  47. Borgdorff P, Tangelder GJ (2013) Migraine relief by chilis and other alternative medications—caused by platelet inhibition? Headache 53(2):386–387

    Article  PubMed  Google Scholar 

  48. Shezad A, Rehman G, Lee Young Sup (2013) Curcumin in inflammatory diseases. Bio Factors 39(1):69–77

    Google Scholar 

  49. Yeon KY, Kim SA, Kim YH, Lee MK, Ahn DK, Kim HJ et al (2010) Curcumin produces an antihyperalgesic effect via antagonism of TRPV1. J Dent Res 89:170–174

    Article  CAS  PubMed  Google Scholar 

  50. Sharma S, Kulkarni SK, Agrewala JN, Chopra K (2006) Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. Eur J Pharmacol 536:256–261

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

S. Cevoli and D. Cologno do not have actual or potential conflict of interest in relation to this article. G. D’Andrea is president and sole administrator of Pharmaval®.

Author information

Authors and Affiliations

  1. Research and Innovation, Corso Stati Uniti 4, 36127, Padua, Italy

    G. D’Andrea

  2. UOC Clinica Neurologica, IRCCS of Neurological Sciences of Bologna, Via Altura 3, 40139, Bologna, Italy

    S. Cevoli

  3. Department of Neuroscience, Institute of Clinical Neurophysiology, Azienda Ospedaliero-Univeristaria OO.RR.Riuniti di Foggia, Viale L.Pinto 1, 71122, Foggia, Italy

    D. Cologno

Authors
  1. G. D’Andrea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Cevoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Cologno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. D’Andrea.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

D’Andrea, G., Cevoli, S. & Cologno, D. Herbal therapy in migraine. Neurol Sci 35 (Suppl 1), 135–140 (2014). https://doi.org/10.1007/s10072-014-1757-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-014-1757-x

Keywords

Search

Navigation